Rekombinanter IL4 (Pascolizumab Biosimilar) Antikörper

Produktnummer ABIN7543171

Produktdetails anti-IL4 (Pascolizumab Biosimilar) Antikörper

Target: IL4 (Pascolizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser IL4 (Pascolizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA, Blocking Reagent (BR), Functional Studies (Func), Inhibition Assay (InhA)

Verwendungszweck: Anti-IL-4 [SB240683 (Pascolizumab, humanized 3B9)], Rabbit IgG, kappa

Spezifität: This antibody binds human and cynomolgus monkey IL-4 and does not cross react with IL-4 from mouse, rat, cow, goat or horse. It does show binding to glycosylated interleukin-4. Interleukin-4 is a receptor for both interleukin 4 and interleukin 13. It couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.

Kreuzreaktivität: Cynomolgus

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: The original mouse antibody was generated by immunizing F1 hybrids of Balb/c and C57BL/6 mice with recombinant human IL-4 in Freunds complete adjuvant. The humanized version was generated by grafting CDRs of murine parent antibody onto human IgG1 kappa heavy- and light-chain frameworks.

Klon: SB240683

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: The original mouse version of this antibody can recognize recombinant human IL-4 in an ELISA and is also capable of inhibiting IL-4 dependent T-cell proliferation in vitro (PMID: 7517357). Binding of this humanized antibody completely blocks the binding of IL-4 to IL-4R. An in vitro study demonstrated that pascolizumab effectively neutralized IL-4 bioactivity in human cell lines including inhibited the proliferation of human T cells, human B cells and TF-1 cells, inhibition of interleukin-4-dependent IgE production by human PBMCs and up-regulation of Fc RII. It also inhibited the early events of asthma including TH2 cell differentiation, eosinophilia and IgE up-regulation. In vivo pharmacokinetic and chronic safety testing in cynomolgus monkeys demonstrated that pascolizumab was well tolerated without inducing adverse clinical responses (PMID:12296858). The pharmacokinetics of the human version of this antibody in the male Sprague Dawley rat was studied and the half life of the antibody was determined to be 11 days (US5914110A). A Phase I trial with a single intravenous dose in mild to moderate asthma demonstrated that it was well tolerated and had an elimination half-life of more than 2 weeks (Shames et al., 2001). However, a subsequent large-scale, multidose phase II trial in steroid-naive subjects with asthma was terminated because preliminary data showed that pascolizumab did not provide clinical benefit (clinical trials: NCT00024544).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu IL4 (Pascolizumab Biosimilar)

Target: IL4 (Pascolizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: IL4, BSF-1, Interleukin-4, B-cell stimulatory factor 1, Binetrakin, Lymphocyte stimulatory factor 1, Pitrakinra

UniProt: P05112